Crizanlizumab and sickle cell disease: When should medications have their approval status revoked? Jacobs JW, Stephens LD, Chooljian DM, Sharma D, et al. Am J Hematol 2024;99:1016-1018.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jacobs JW, Stephens LD, Chooljian DM, Sharma D, et al. Crizanlizumab and sickle cell disease: When should medications have their approval status revoked? Am J Hematol 2024;99:1016-1018.
PMID: 38409818